在人体淋巴细胞培养中使用co-codamol的基因毒性在体外
Sada Jasim Abdulameer1, Anfal Izaldeen Alkateeb2, Layth Ammar Chyad Al-Shammari3
1Science Department, College of Basic Education, University of Wasit, Iraq. sabdulameer@uowasit.edu.iq.
Cellular and molecular biology (Noisy-le-Grand, France)
|July 30, 2025
概括
一种止痛药Co-codamol在人体淋巴细胞中显示出基因毒性潜力. 这项研究发现,它会损害DNA,降低细胞活力,增加染色体异常和微核形成.
科学领域:
- 药理学和毒理学 药理学和毒理学
- 遗传学和分子生物学
背景情况:
- 可达摩尔 (Co-codamol) 是和可代因酸盐的组合,是一种常见的止痛药.
- 科科达摩尔对人体淋巴细胞的基因毒性作用尚未得到充分证实.
研究的目的:
- 研究co-codamol在人体淋巴细胞上的体外基因毒性潜力.
- 评估co-codamol对细胞活力,线粒体指数,染色体异常和微核形成的影响.
主要方法:
- 人类淋巴细胞被培养并暴露于不同度的co-codamol (0.02-0.12 mg/mL).
- 用MTT测定来评估细胞毒性.
- 评估了线粒体指数,染色体异常频率和微核形成.
主要成果:
- 可可达摩尔显著降低了淋巴细胞活力,以剂量依赖的方式,导致0.12 mg/mL的完整细胞死亡.
- 在较高度下观察到线粒体指数的显著下降.
- 与对照细胞相比,在用co-codamol治疗的淋巴细胞中,染色体异常和微核形成的统计显著增加 (p < 0.05).
结论:
- 可达摩尔在体外表现出基因毒性潜力,表明存在DNA损伤的风险.
- 这些发现表明,有关使用co-codamol的潜在临床担忧.
- 需要进一步的体内研究来确认这些遗传毒性作用,并了解毒性的机制.
相关概念视频
01:25Mutagenicity and Carcinogenicity
1.4K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.4K
01:16In-vitro Mutagenesis
14.2K
To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
14.2K